trial
as of 2026-07-01Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia
NCTId NCT02639702
at a glance
Phase 4 · Recruiting
Enrollment 30 (estimated)
Sponsored by Centre for Addiction and Mental Health
Primary completion 2026-12
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Recruiting
Enrollment
30 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2016-08
Primary completion
2026-12
Eligibility
ALL · 18 Years
Interventions & indications
Sponsors
Centre for Addiction and Mental HealthLead Sponsor
Investigators
1
Gary Remington, MD PhD FRCPCPrincipal Investigator
Sites
1 total
Toronto, Canada
Facts & assertions
4 sourced
Enrollment
30
Phase
PHASE4
Primary Completion Date
2026-12
Status
RECRUITING
relationships
The graph out of here
drug
drug
lead_sponsor
indication
investigator